Maxim Group analyst Michael Okunewitch has maintained their bullish stance on LGVN stock, giving a Buy rating yesterday.
Michael Okunewitch has given his Buy rating due to a combination of factors related to Longeveron’s promising developments in their clinical programs. The ELPIS II study for laromestrocel (Lomecel-B) has reached 90% enrollment, indicating strong progress towards its completion in the second quarter of 2025. This study is crucial as it aims to demonstrate the efficacy of laromestrocel in treating hypoplastic left heart syndrome (HLHS), with topline data expected by mid-2026. The study’s design and the potential for a six-month review due to the rare pediatric nature of the disease position Longeveron well for a possible approval in 2027, assuming positive data outcomes.
Additionally, Longeveron’s Alzheimer’s disease program is advancing, with an upcoming FDA meeting expected to clarify the regulatory path forward. The company is seeking a streamlined approval process, which could enhance its competitiveness in securing partnerships. The study’s funding through a National Institute of Health grant, coupled with rare pediatric disease, orphan drug, and fast-track designations, provides financial support and potential non-dilutive funding opportunities. These strategic moves and the positive long-term survival data from previous studies contribute to the optimistic outlook and Buy rating.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $10.00 price target.
LGVN’s price has also changed moderately for the past six months – from $2.170 to $1.330, which is a -38.71% drop .
Questions or Comments about the article? Write to editor@tipranks.com